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Abstract The programmed cell death 5 (PDCD5) protein is a
novel protein related to regulation of cell apoptosis. In this
report, we demonstrate that the level of PDCD5 protein
expressed in cells undergoing apoptosis is significantly increased
compared with normal cells, then the protein translocates rapidly
from the cytoplasm to the nucleus of cells. The appearance of
PDCD5 in the nuclei of apoptotic cells precedes the externaliza-
tion of phosphatidylserine and fragmentation of chromosome
DNA. This phenomenon is parallel to the loss of mitochondrial
membrane potential, independent of the feature of apoptosis-
inducing stimuli and also independent of the cell types and the
apoptosis modality. In conclusion, the nuclear translocation of
PDCD5 is a universal earlier event of the apoptotic process, and
may be a novel early marker for apoptosis. ß 2001 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Apoptosis is a form of cellular suicide that is widely ob-
served in nature. This process can be triggered by a variety of
physiological and pathological stimuli, including radiation,
drugs, growth factor deprivation, hormones and stress [1^3].
Many apoptosis-related genes and their products have been
found which take part in the regulation of the apoptosis pro-
cess, including the caspase, BcL-2, tumor necrosis factor
(TNF)/FasL, and oncogenes families [4].
TF-1 cell apoptosis related gene-19, also designated
PDCD5 (programmed cell death 5) by the International Hu-
man Gene Nomination Committee, is a novel gene cloned
from TF-1 cells undergoing apoptosis [5]. PDCD5 protein is
conservative in the process of evolution and has signi¢cant
homology to the corresponding proteins of species ranging
from yeast to mice [5,6].
Early studies indicated that recombinant human PDCD5
could accelerate apoptosis of some tumor cells (HeLa, TF-1,
HL60, MCG-803, MCF-7) [5,7]. In order to further study the
biological activities of PDCD5, we successfully produced spe-
ci¢c monoclonal antibodies against PDCD5. Then, we used
these monoclonal antibodies as probes to observe the expres-
sion and localization of PDCD5 in cell apoptosis process. We
demonstrate that PDCD5 protein can translocate to the nu-
cleus rapidly in cells undergoing apoptosis and the accumu-
lation of PDCD5 in the nucleus precedes the chromosome
DNA fragmentation and phosphatidylserine (PS) externaliza-
tion.
2. Materials and methods
2.1. Reagents
Etoposide (VP16), staurosporin, camptothecin, propidium iodide
(PI), Rhodamine123 and 4,6-diamidino-2-phenylindole-dihydrochlo-
ride (DAPI) were purchased from Sigma. Horseradish peroxidase
(HRP)-conjugated anti-mouse IgG was from Promega. Enhanced lu-
minol chemiluminescence reagent was obtained from NEN1 Life Sci-
ence Products. Dulbecco’s modi¢ed Eagle’s medium (DMEM) and
RPMI 1640 were obtained from Gibco BRL. Fetal calf serum
(FCS) was from Hyclone. Complete protease inhibitor cocktail was
procured from Boehringer Mannheim.
2.2. Cell culture and apoptosis induction
TF-1 cells were cultured in RPMI 1640 medium supplemented with
10% FCS in the presence or absence of 40 ng/ml of recombinant
human granulocyte macrophage colony-stimulating factor (GM-
CSF). HeLa, HEK293, 293T (SV40 large T antigen) and HEC-1a cells
were cultured in DMEM containing 10% FCS. K562 cells were cul-
tured in RPMI 1640 medium supplemented with 10% FCS and 2 mM
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. For in-
duction of apoptosis, HEK293, HeLa, HEC-1a and K562 cells were
cultured in the presence of VP16; HeLa cells were also cultured in the
presence of staurosporin, camptothecin, cisplatin and UV-irradiation.
2.3. Preparation of monoclonal antibodies against PDCD5
Balb/c mice were immunized with recombinant human PDCD5
protein [7], and spleen cells were fused with the mouse myeloma
Sp2/0 in the presence of polyethylene glycerol as previously described
[8,9]. Hybridoma cell lines producing antibodies were screened by
indirect ELISA. One clone, named 3A3, was subcloned by limiting
dilution and ascites £uid prepared using pristine primed Balb/c mice.
3A3 IgG was puri¢ed with Hitrap1 proteinG (Amersham Pharmacia
Biotech). FITC-labeling of the puri¢ed IgG was prepared as previ-
ously described [10].
2.4. Immuno£uorescence
At indicated time points, cells were washed with cold phosphate-
bu¡ered saline (PBS), ¢xed with freshly prepared 3% paraformalde-
hyde (10 min on ice), followed by the addition of PBS containing
0.2% Tween 20 for 15 min at 37‡C. Cells were blocked with FCS
and incubated with FITC-3A3 IgG for 30 min at 4‡C. DAPI
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(0.5 Wg/ml) was added for 15 min to visualize the cell nuclei. Washed
cells were subsequently analyzed using FACScan £ow cytometer (Bec-
ton Dickinson), Leica £uorescence microscope or Leica TCS NT con-
focal laser scan microscope (CLSM).
2.5. Western blotting
Cells were washed in ice-cold PBS and resuspended in lysis bu¡er
containing 10 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM
EDTA, 1% Triton X-100, 0.2 mM sodium orthovanadate and the
protease inhibitor cocktail for 30 min on ice. The lysates were then
centrifuged at 14 000Ug for 15 min and the supernatant was quanti-
¢ed by protein assay kit. An equal amount of extracted protein was
separated by 15% SDS^PAGE and then transferred to nitrocellulose
membrane. The membrane was blocked overnight in TBS containing
5% non-fat dried milk and 0.05% Tween 20 and then incubated for 1 h
with monoclonal antibody against PDCD5 (3A3). After washing,
the membrane was incubated with an HRP-conjugated secondary
antibody and the bound antibody was visualized using enhanced
chemiluminescence detection system.
2.6. Detection of DNA fragmentation
TF-1 cells (5^10U106) were cultured as described above. Nuclear
DNA from lysed cells, treated with protease K and RNase according
to standard protocols, was subjected to conventional horizontal aga-
rose gel electrophoresis (1.2%) followed by ethidium bromide staining
[11].
2.7. Detection of PS externalization
Treated TF-1 cells (0.5U106) were washed and resuspended in
binding bu¡er containing annexin-V-FITC (25 Wg/ml) and PI (5 Wg/
ml) for 15 min prior to analysis. Ten thousand cells were collected on
a FACScan £ow cytometer equipped with a 488 nm argon laser and
analyzed using the CellQuest software (Becton Dickinson).
2.8. Transient transfection
The construction of mammalian expression vector pEGFPC3^
PDCD5 containing EGFP^human PDCD5 (full-length open reading
frame) fusion gene has been described previously [5]. HeLa cells and
293T cells grown on 12 mm glass coverslips in 6-well plates were
transfected at 60^80% con£uence with pEGFPC3^PDCD5 and
pEGFPC3 plasmids by Superfect Transfection Reagent according to
the manufacturer’s directions. After 24 h, 85 Wm of VP16 was added
to the 293T cell medium and cell localization of EGFP^PDCD5 was
observed at di¡erent time points with £uorescence microscope. In
addition, the nuclear transportation of PDCD5 in a single HeLa
cell treated with staurosporin (1 WM) was analyzed under the
CLSM. At the same time, for in situ analysis of apoptosis, cells
were stained with R-PE annexin-V (Pharmingen) and PI.
2.9. Detection of mitochondrial membrane potential
The mitochondrial membrane potential was determined by the re-
tention of £uorescent dye Rhodamine123 [12]. After the drug treat-
ment, 5U105 cells in 1 ml complete DMEM were stained with the
Rhodamine123 (1 WM) for 30 min at 37‡C prior to the £ow cytometric
analysis. The same incubation time was applied to the untreated cells.
3. Results
3.1. TF-1 cell apoptosis is concomitant with nuclear
translocation of PDCD5
TF-1 cell line is a human premyeloid cell established from a
Fig. 1. Apoptotic features in TF-1 cells after GM-CSF deprivation. A: Detection of DNA fragmentation in TF-1 cells cultured in GM-CSF-
free medium for the indicated times. B: Time course of PS externalization and PI uptake. Cells were cultured in GM-CSF-free medium for the
indicated periods and PS externalization and PI uptake were determined by £ow cytometry (see Section 2). Similar experiments were done in
duplicate.
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patient with erythroleukemia. Their survival and proliferation
are dependent on interleukin-3, GM-CSF, EPO or other cy-
tokines [5,13]. After GM-CSF deprivation, TF-1 cells were
found to exhibit the features of apoptosis, including conden-
sation of chromatin, blebbing of the cytoplasmic membrane,
cell shrinking, externalization of PS and the formation of
DNA fragmentation (Fig. 1A,B). Flow cytometric detection
of PDCD5 protein using FITC-labeled anti-PDCD5 antibody
showed that PDCD5-positive cells and £uorescence intension
increased rapidly in TF-1 cells after GM-CSF deprivation,
exhibited a time-dependent increase and then declined (Fig.
2A). Western blot analysis showed that the PDCD5 protein
expressed in apoptotic TF-1 cells was higher than that ex-
pressed in normal TF-1 cells (Fig. 2B). Using the Leica £uo-
rescence microscope and CLSM, signi¢cant nuclear transloca-
tion of PDCD5 was observed in TF-1 cells after GM-CSF
deprivation (Fig. 3). In untreated TF-1 cells, PDCD5 protein
was weakly expressed and localized in both the cytoplasm and
nucleus. After GM-CSF deprivation for 8 h, more than 75%
of the cells displayed a nuclear accumulation of PDCD5 pro-
tein, here in a condensed form. PDCD5 was also observed in
the apoptotic small bodies after GM-CSF deprivation for 36 h.
Interestingly, accumulation of PDCD5 in the nucleus of TF-1
cells precedes DNA fragmentation and PS externalization
(Figs. 1 and 3). It is therefore suggested that the phenomenon
may be an earlier phase event during cell apoptosis.
3.2. Nuclear translocation of PDCD5 is a widespread
phenomenon during the apoptosis of cells
To determine whether the nuclear translocation of PDCD5
is a general accompaniment to apoptosis, we extended our
study to investigate other cell types. Interestingly, similar re-
sults were also observed in other cell lines such as HEK293,
HEC-1a, K562, and HeLa cells treated with VP16 (Fig. 4A).
This was con¢rmed by pEGFPC3^PDCD5 plasmid transi-
ently transfected 293T cells treated with VP16 (Fig. 4B). In
addition, a dynamic nuclear transportation of EGFP^PDCD5
fusion protein in staurosporin-treated transfected HeLa cells
was observed by CLSM. Before treatment, pEGFP^PDCD5
£uorescence showed a uniform distribution through the whole
cell. After 30 min of treatment with staurosporin (1 WM), a
nuclear accumulation of EGFP^PDCD5 was observed that
later decreased (Fig. 5). However, there was no annexin-V-
R-PE on its surface or PI uptake after 1 h treatment. These
¢nding support a conclusion that nuclear translocation of
PDCD5 in cells undergoing apoptosis may be considered a
universal phenomenon preceding PS externalization and PI
uptake.
3.3. Nuclear translocation of PDCD5 during apoptosis is
stimulus-independent
To determine whether these changes could occur regardless
of the initiating stimulus. We exposed HeLa cells to a range of
apoptosis-inducing agents such as the chemotherapeutic agent
etoposide, camptothecin, cisplatin, a protein kinase C inhib-
itor staurosporin, growth factor deprivation and UV light.
Figure 6A demonstrates that nuclear translocation of
PDCD5 accompanies apoptosis of HeLa cells in response to
all of the agents tested. However, the rate of nuclear trans-
portation of PDCD5 is di¡erent. This is accounted for by the
fact that HeLa cells utilize di¡erent stress mechanisms in re-
sponse to various stimuli. Taken together, these data provide
compelling evidence for a tight association between apoptosis
and nuclear translocation of PDCD5, regardless of the cell
Fig. 2. Expression of PDCD5 in TF-1 cells after GM-CSF depriva-
tion. A: Time course of mean £uorescence intensity of PDCD5 ana-
lyzed by £ow cytometry. B: Western blot analysis of expression of
PDCD5 in TF-1 cells after GM-CSF withdrawal for 10 h and 0 h.
Equal amounts of cell lysates were separated on 15% SDS^PAGE
gels and probed with antibody speci¢c to PDCD5. Similar experi-
ments were done in duplicate.
Fig. 3. CLSM evidence for the nuclear translocation of PDCD5 in TF-1 cells after GM-CSF deprivation. A: Cells were stained with FITC-la-
beled 3A3 antibody at di¡erent time points, and observed using CLSM. B: Cells were cultured in GM-CSF-free medium for 16 h, then stained
with FITC-3A3 and DAPI. Nuclear accumulation of PDCD5 and condensed nuclei were obviously observed.
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Fig. 4. Fluorescence microscope evidence for nuclear translocation of PDCD5 in di¡erent cell types. A: HeLa and HEC-1a cells were treated
with 85 WM of VP16; K562 cells treated with 170 Wm of VP16; HEK293 cells treated with 68 WM of VP16. B: 293T cells were transiently
transfected with pEGFP and pEGFP^PDCD5 for 24 h, then treated with 85 WM of VP16 at di¡erent time points. (488 nm, U400).
Fig. 5. Kinetic analysis of localization of EGFP^PDCD5 fusion protein in HeLa cells treated with staurosporin (1 Wm) for indicated time
points (A and B). HeLa cells were transiently transfected with pEGFP^PDCD5 plasmid for 24 h, then 1 Wm of staurosporin was added to cul-
tures. After 30 min of treatment, accumulation of EGFP^PDCD5 fusion protein in cell nuclei was clearly observed.
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type or apoptosis-inducing stimulus. In addition, when HeLa
cells were treated with staurosporin (0.15 WM), a transient
cytoplasmic accumulation of PDCD5 was observed after 2 h
and was translocated rapidly to the nucleus. In contrast, an-
nexin-V-binding cells were apparent at 5 h and later (Fig. 6B).
3.4. PDCD5 translocation and mitochondrial membrane
potential
The mitochondrial membrane potential (v8mt) was moni-
tored by cationic £uorescent probe Rhodamine123. HeLa cells
were treated with staurosporin (0.5 WM) at several time
points, after which, they were stained with 1 Wm Rhod-
amine123. A marked decrease of £uorescence intensity was
observed after treatment for 3 h. This re£ects the drug-in-
duced depolarization of the inner mitochondrial membrane.
At this time point, more than 60% of HeLa cells treated with
staurosporin had nuclear accumulation of PDCD5 (Fig. 7),
which indicates that PDCD5 translocation is parallel to the
decrease of v8mt.
4. Discussion
PDCD5 is a novel protein related to the apoptosis process
of cells. In this report, we ¢rst demonstrated that PDCD5,
normally uniformly distributed among the cells, was rapidly
translocated to the nucleus of target cells undergoing apopto-
sis. In addition, we found that the nuclear accumulation of
PDCD5 preceded the externalization of PS and the formation
of DNA fragmentation. This phenomenon is perhaps a very
early common event of cell apoptosis, parallel to the loss of
mitochondrial membrane potential, independent of the apo-
ptosis-inducing stimuli (protein kinase inhibitor, topoisomer-
ase I or II inhibitors, UV light and growth factor depriva-
tion), and also independent of the cell types and the apoptosis
modality (from early apoptosis to later apoptosis) (Figs. 3^6).
The mechanism that results in nuclear translocation of
PDCD5 is unclear at present. Since PDCD5 does not contain
a linear or bipartite nuclear localization signal [14,15], there
remains a distinct possibility that some carrier proteins facil-
itate the nuclear transportation of PDCD5 [16] or alterna-
tively, perhaps there is an uncovered nuclear localization sig-
nal within the PDCD5 protein. Recent reports in apoptosis
research have focused on the nuclear morphological changes
characteristic of apoptosis [17,18]. Nuclear changes are dis-
tinct hallmarks during the cell apoptosis process. Several
stages of nuclear apoptosis can be distinguished: stage I
with rippled nuclear contours and a rather partial chromatin
condensation; stage IIa having marked peripheral chromatin
condensation; and, stage IIb showing the formation of nu-
clear small bodies [19]. Kinetic studies reveal that these stages
actually re£ect successive steps in the apoptotic process. Stage
I is also called pre-apoptotic nuclei, and happens in the early
stage of cell apoptosis [20]. Ultra-structure analysis reveals
that this pre-apoptotic nucleus is characterized by heavily
convoluted nuclei with numerous cavitations. It is closely as-
sociated with high molecular size DNA fragmentation. How-
ever, there is little evidence of molecular changes in this stage.
Our studies hint that an interesting link might be established
between the nuclear transportation of PDCD5 and the for-
mation of pre-apoptotic nuclear morphological changes.
Fig. 6. Nuclear translocation of PDCD5 in HeLa cells treated with
a variety of stimuli. A: Cells were cultured in serum-free medium
for 48 h; exposed to cisplatin (33 WM, 16 h), camptothecin (2.8 Wm,
16 h), staurosporin (0.5 WM, 4 h) and etoposide (68 WM, 8 h); UV
irradiation for 9 h. B: Comparison of nuclear translocation of
PDCD5 and PS externalization. HeLa cells were treated by stauro-
sporin (0.15 WM) at 0 (a), 2 (b), 3 (c), and 5 h (d). At these time
points, cells that were stained with FITC-3A3 (a^c) and annexin-V-
FITC (d) indicated that nuclear translocation of PDCD5 precedes
the externalization of PS.
Fig. 7. Analysis of the nuclear translocation of PDCD5 in HeLa
cells treated with staurosporin (0.5 Wm) for indicated time points.
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The binding of annexin-V on cells undergoing apoptosis has
been proposed to be an early event based on correlative stud-
ies with cell populations [21]. Recent studies have found that
annexin-V-binding cells have a high degree of DNA fragmen-
tation [22]. Therefore, these two markers of apoptosis do not
explain the much earlier changes of the cell apoptosis process.
It is important to note that once PDCD5 enters the nucleus, it
runs through the whole apoptotic process for cells (from early
apoptosis to later apoptosis or death). Perhaps this would be
a useful marker to account for an early event in the process of
cell apoptosis and initial apoptotic changes in the nucleus.
Combined with other conventional apoptotic markers (such
as PS externalization, DNA fragmentation), it will be also
helpful to surveillance the whole process of cells apoptosis.
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